Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) Sees Large Growth in Short Interest

Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) was the target of a large growth in short interest in the month of October. As of October 15th, there was short interest totaling 6,600 shares, a growth of 61.0% from the September 30th total of 4,100 shares. Based on an average daily trading volume, of 27,400 shares, the short-interest ratio is currently 0.2 days. Currently, 0.7% of the shares of the company are sold short. Currently, 0.7% of the shares of the company are sold short. Based on an average daily trading volume, of 27,400 shares, the short-interest ratio is currently 0.2 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Addex Therapeutics in a report on Tuesday, October 14th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

Addex Therapeutics Stock Up 0.3%

Shares of NASDAQ:ADXN opened at $9.14 on Tuesday. The company has a market cap of $9.68 million, a PE ratio of -1.56 and a beta of 1.38. The company’s 50-day moving average price is $9.04 and its 200 day moving average price is $8.57. Addex Therapeutics has a fifty-two week low of $6.51 and a fifty-two week high of $12.05.

Addex Therapeutics (NASDAQ:ADXN) last issued its quarterly earnings data on Monday, September 29th. The company reported ($2.91) earnings per share for the quarter. Addex Therapeutics had a net margin of 3,584.49% and a negative return on equity of 68.40%.

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.